HCAR2

Across TCGA pan-cancer cohorts, HCAR2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HCAR2 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher HCAR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HCAR2 expression acts as an unfavorable survival marker.

BLCA, ESCA, and DLBC are the cancer types where HCAR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.293	0.715	<.001	48	view →
ESCA	DFS	Median	II,III,IV	0.141	0.529	<.001	18	view →
DLBC	DFS	Median	II,III,IV	0.022	0.837	<.001	12	view →
BRCA	OS	Median	All	0.306	0.924	<.001	12	view →
STAD	OS	Median	All	0.091	0.538	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HCAR2–BLCA (OS)

Open the BLCA breakdown →